Prodrug applications for targeted cancer therapy

Area of Science:

• Oncology
• Medicinal Chemistry
• Biotechnology
• Polymer Science

Background:

• Prodrugs are crucial for targeted delivery of cytotoxic agents in cancer therapy.
• Current prodrug strategies exhibit diversity in targeting, activation, and physicochemical properties.
• Macromolecular prodrugs, including antibody-drug conjugates and polymer-drug conjugates, are a significant trend.

Purpose of the Study:

• To provide a unified perspective on cancer-targeted prodrugs.
• To highlight novel prodrug concepts emerging from recombinant technology.
• To explore conditional targeting strategies for enhanced specificity in cancer treatment.

Main Methods:

• Review of existing literature on cancer-targeted prodrugs.
• Analysis of recombinant technologies, exemplified by engineered anthrax toxin.
• Exploration of structural complementation for conditional and bispecific targeting.

Main Results:

• Recombinant 'prodrugs' demonstrate potential for high biological specificity via conditional targeting.
• Engineered anthrax toxin utilizes structural complementation for conditional targeting of multiple markers.
• Complementing systems can be adapted for bispecific enzyme activation of low-molecular-weight prodrugs.

Conclusions:

• Prodrugs, integrating medicinal chemistry, polymer science, and recombinant technology, are key to tailored cancer therapies.
• Conditional targeting strategies offer precise approaches to attack complex molecular phenotypes in cancer.
• The future of prodrug development lies in leveraging interdisciplinary strengths for advanced cancer treatment.